Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
暂无分享，去创建一个
[1] Susan M. Chang,et al. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival , 2023, Neuro-oncology.
[2] G. Parmigiani,et al. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Brandes,et al. End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era , 2011, Expert review of anticancer therapy.
[4] B. Kramer,et al. A perfect correlate does not a surrogate make , 2003, BMC medical research methodology.
[5] D. DeMets,et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.
[6] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[7] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.